shutterstock-61613566-vittorio-bruno
Vittorio Bruno / shutterstock.com
12 October 2016AmericasSandra Kuzmich and Russell Garman

Life Technologies v Promega: the long tentacles of infringement

After hearing three patent cases in its last term, the US Supreme Court agreed in June to take on another: Life Technologies et al v Promega et al. The Supreme Court’s focus will be on the meaning of a particular phrase—“substantial portion”—that appears in 35 USC §271(f)(1). This section of the patent statute governs infringement in circumstances where components from the US are shipped abroad for inclusion in a combination that would have infringed a patent had the combination been manufactured in the US.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
27 February 2026   The companies have agreed to dismiss their long-running patent fight over tumour-informed liquid biopsy technology, closing a high-stakes chapter in the fast-growing MRD testing market—while leaving the door open to future claims.
Americas
26 February 2026   As the US Supreme Court prepares to hear arguments in the Hikma and Amarin dispute, the case has drawn a broad coalition of industry support—including the US government and a co-author of the Hatch-Waxman Act itself.
Americas
26 February 2026   In a decision with implications for biotechnology licensing and pharmaceutical manufacturing, the Ninth Circuit has rejected a ‘sweeping’ royalty trigger from a lower court.